Table 1 Patient Demographics and Characteristics

Gender (male), n (%)

14 (39)

Age at diagnosis, median, (IQR), years

6.5 (4.4–10.9)

Age at start adalimumab, median (IQR), years

10.5 (6.0–12.0)

Age at adalimumab through level, median (IQR), years

11.3 (7.1–13.0)

Time from diagnosis to adalimumab initiation, median (IQR), months

11.5 (4–33.5)

Time from adalimumab initiation to TL, median (IQR), weeks

37.5 (21–268)

Disease duration at TL, median (IQR), months

25.2 (12–56)

Weight at TL, median (IQR), kg

35 (21–52)

Weight corrected dose at TL, median (IQR), mg/kg body weight

0.85 (0.7–1.1)

Anatomical location of uveitis n (%)

 Anterior uveitis

24 (67)

 Intermediate uveitis

6 (17)

 Posterior uveitis

2 (6)

 Panuveitis

4 (11)

Anterior chamber cell count — no. (%)*

 0.5 + 

9 (25)

 1 + 

14 (39)

 2 + 

12 (33)

 3 + 

1 (3)

Laterality, n (%)

 Unilateral

11 (31)

 Bilateral

25 (69)

Etiological diagnosis n (%)

 Juvenile idiopathic arthritis

19 (53)

 Sarcoidosis

2 (6)

 Idiopathic

15 (42)

Treatment

 Previous Immunomodulators n (%)

  Oral corticosteroids

13 (36)

  Methotrexate

31 (86)

  Cyclosporin A

4 (11)

  Mycophenolate mofetil

1 (3)

  Tacrolimus

1 (3)

  Etanercept

1 (3)

 Concomitant Immunomodulators n (%)

  Methotrexate

21 (58)

  Tacrolimus

1 (3)

Uveitis complications n (%)

 Ocular hypertension/glaucoma

3 (8)

 Cataract

9 (25)

 Band keratopathy

4 (11)

 Cystoid Macular edema

11 (31)

 Macular epiretinal membrane

3 (8)

 Optic disc swelling

5 (14)

 Posterior synechia

11 (31)

Development of ADA, n (%)

2 (6)